Neovasc a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced on wednesday the 22nd may that the International Journal of Cardiology has published a peer reviewed article regarding long term sustained efficacy and safety of the Reducer therapy in 50 patients suffering from refractory disabling angina. The title of the article is: "Safety and efficacy of Coronary Sinus Reducer implantation at 2-year follow-up."
This study shows us that the Reducer has a sustained therapeutic effect at two years across a large patient population. In addition, we believe this study provides valuable long-term safety data that further supports cardiologists use of the Reducer as a therapeutic option for patients suffering from refractory angina," commented Prof. Shmuel Banai, Medical Director of Neovasc. "This data supports our belief that the Reducer offers refractory angina patients a safe and effective treatment option, filling a void in a market where there are currently limited therapeutic options."
The stock very well have a 100% move in the coming days so don't be caught napping. Currently sitting below resistance at $.76 a break above $.9 opens the door to the bulls.
AVERAGE TARGET PRICE $2.51
AVERAGE RECOMMENDATION OVERWEIGHT
NEOVASC INC.
Neovasc, Inc. engages in the development, manufacture and marketing of medical devices. Its focuses on Neovast Tiara, and Neovasc Reducer products
This study shows us that the Reducer has a sustained therapeutic effect at two years across a large patient population. In addition, we believe this study provides valuable long-term safety data that further supports cardiologists use of the Reducer as a therapeutic option for patients suffering from refractory angina," commented Prof. Shmuel Banai, Medical Director of Neovasc. "This data supports our belief that the Reducer offers refractory angina patients a safe and effective treatment option, filling a void in a market where there are currently limited therapeutic options."
The stock very well have a 100% move in the coming days so don't be caught napping. Currently sitting below resistance at $.76 a break above $.9 opens the door to the bulls.
AVERAGE TARGET PRICE $2.51
AVERAGE RECOMMENDATION OVERWEIGHT
NEOVASC INC.
Neovasc, Inc. engages in the development, manufacture and marketing of medical devices. Its focuses on Neovast Tiara, and Neovasc Reducer products